Mutational data and gene expression data (pan-cancer normalized) are available for a limited number of patients only; nevertheless, KRAS activating mutations exhibited similar synergistic relationship with CIP2A expression levels as did high KRAS expression (Fig. 7a). The gene discussed is KRAS; the disease is cancer.